DeepMed Research

Jiangsu Hengrui Medicine Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Phase 3

Completed

Conditions: Severe Aplastic Anemia

Interventions: Drug: Hetrombopag Olamine+Standard Therapy
Drug: Placebo+Standard Therapy

First Posted Date: 2019-01-31

Last Posted Date: 2024-11-07

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT03825744

Locations: 🇨🇳
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer

Phase 3

Completed

Conditions: GastroEsophageal Cancer
Gastric Cancer

Interventions: Drug: SHR-1210
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Apatinib

First Posted Date: 2019-01-23

Last Posted Date: 2024-11-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 885

Registration Number: NCT03813784

Locations: 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China

Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy

Phase 3

Completed

Conditions: Sedation

Interventions: Drug: Propofol
Drug: Remimazolam Tosilate

First Posted Date: 2018-12-19

Last Posted Date: 2018-12-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 388

Registration Number: NCT03779061

Locations: 🇨🇳
Clinical trial Ethnics Committee of Peking Union Medical College Hospital, Beijing, Beijing, China

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2

Conditions: KRAS Gene Mutation
PD-1 Antibody
NSCLC Stage IV
Chemotherapy Effect

Interventions: Drug: SHR-1210
Drug: Pemetrexed
Drug: Apatinib
Drug: Carboplatin

First Posted Date: 2018-12-17

Last Posted Date: 2019-01-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 230

Registration Number: NCT03777124

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase 1

Conditions: Solid Tumor

Interventions: Drug: SHR-1701

First Posted Date: 2018-12-13

Last Posted Date: 2022-11-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 193

Registration Number: NCT03774979

Locations: 🇨🇳
Anhui Chest Hospital-Departmen of Tumor Radiotherapy, Hefei, Anhui, China
🇨🇳
Hunan Cancer Hospital-Gynecologic Oncology, Changsha, Hunan, China
🇨🇳
Xinxiang Central Hospital-Department of Respiratory Physicians, Xinxiang, Henan, China

and more 13 locations

The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: SHR2285
Drug: Placebo

First Posted Date: 2018-12-10

Last Posted Date: 2021-05-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT03769831

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3

Completed

Conditions: Locally Advanced or Metastatic and Unresectable HCC

Interventions: Drug: Sorafenib
Drug: SHR-1210
Drug: Apatinib

First Posted Date: 2018-12-05

Last Posted Date: 2024-02-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 543

Registration Number: NCT03764293

Locations: 🇺🇸
Renovatio Clinical, The Woodlands, Texas, United States
🇨🇳
The 940th Hospital of the joint logistic support force of People's Liberation Army, Lanzhou, Gansu, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 118 locations

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Phase 1

Terminated

Conditions: Castration-resistant Prostate Cancer
Prostate Cancer

Interventions: Drug: SHR2554
Drug: SHR3680

First Posted Date: 2018-11-15

Last Posted Date: 2021-02-05

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT03741712

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Phase 2

Conditions: Advanced Esophageal Squamous Cell Cancer

Interventions: Drug: Irinotecan liposome
Drug: SHR-1316
Drug: Fluorouracil

First Posted Date: 2018-11-06

Last Posted Date: 2018-11-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT03732508

Locations: 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Phase 1

Suspended

Conditions: Lymphoma
Hematologic Neoplasms
Immunotherapy
Neoplasms by Histologic Type
Physiological Effects of Drugs
Advanced Cancer

Interventions: Drug: SHR-1603

First Posted Date: 2018-10-26

Last Posted Date: 2021-03-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 128

Registration Number: NCT03722186

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy